Regulation of p21waf1/cip1 by Rho and Ras signaling

Rho 和 Ras 信号传导对 p21waf1/cip1 的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): Ras GTPase proteins (K-Ras, H-Ras, N-Ras) were first identified because of their association with oncogenic transformation. Activating oncogenic Ras mutations have been found in a variety of tumor types with an overall incidence of approximately 30% in human cancers. Despite the robust transforming ability of oncogenic Ras, additional signaling pathways influence the efficiency of Ras-induced oncogenesis. One signaling protein that contributes to oncogenic transformation by Ras is the Rho GTPase. Inhibition of Rho significantly impairs Ras-driven transformation, while active Rho synergistically co-operates with Ras or with the Ras effector protein Raf to promote transformation. In characterizing the basis of Rho and Ras cooperation, we found that Rho suppresses Ras-induction of the cyclin dependent kinase inhibitor p21Waf1/Cip1 (p21), thereby facilitating cell cycle progression. One mechanism of p21 suppression by Rho is through repression of Ras-induced transcriptional activation. While acute high intensity Ras signaling leads to cell cycle arrest due to the transcriptional up-regulation of p21, cells stably transformed by Ras have high levels of active Rho which suppresses p21 transcription thereby permitting cell cycle progression, p21 protein levels are significantly higher in Ras-transformed cells than in untransformed parental cells, despite comparable levels of p21 mRNA due to Rho-mediated transcriptional suppression, suggesting that posttranscriptional mechanisms are responsible for the elevation in protein levels. These findings raise several key questions. 1) What is the post-transcriptional mechanism that raises p21 protein levels in Ras transformed cells? 2) Does Rho activity squelch p21 levels by post-transcriptional means in addition to transcriptional suppression? 3) What is the pathway downstream of Rho that leads to p21 transcriptional suppression? To answer these questions, we will use cell biological and in vitro biochemical methods. Unlike the p16 cyclin dependent kinase inhibitor which is frequently deleted in tumors with Ras mutations, p21 has not been reported to be lost, suggesting that inhibiting Rho function to elevate p21 levels and arrest cell cycle progression potentially would be an effective anti-cancer therapeutic strategy.
描述(由申请人提供):

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The ras signalling pathway as a target in cancer therapy.
ras 信号通路作为癌症治疗的靶点。
Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration.
基于肌动蛋白肌球蛋白的收缩负责凋亡的核崩解。
  • DOI:
    10.1083/jcb.200409049
  • 发表时间:
    2005-01-17
  • 期刊:
  • 影响因子:
    7.8
  • 作者:
    Croft, DR;Coleman, ML;Li, SX;Robertson, D;Sullivan, T;Stewart, CL;Olson, MF
  • 通讯作者:
    Olson, MF
LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells.
  • DOI:
    10.1083/jcb.201002041
  • 发表时间:
    2010-10-04
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Scott RW;Hooper S;Crighton D;Li A;König I;Munro J;Trivier E;Wickman G;Morin P;Croft DR;Dawson J;Machesky L;Anderson KI;Sahai EA;Olson MF
  • 通讯作者:
    Olson MF
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL FRANCIS OLSON其他文献

MICHAEL FRANCIS OLSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL FRANCIS OLSON', 18)}}的其他基金

Regulation of p21waf1/cip1 by Rho and Ras signaling
Rho 和 Ras 信号传导对 p21waf1/cip1 的调节
  • 批准号:
    6729460
  • 财政年份:
    2003
  • 资助金额:
    $ 18.23万
  • 项目类别:
Regulation of p21waf1/cip1 by Rho and Ras signaling
Rho 和 Ras 信号传导对 p21waf1/cip1 的调节
  • 批准号:
    6807564
  • 财政年份:
    2003
  • 资助金额:
    $ 18.23万
  • 项目类别:
Regulation of p21waf1/cip1 by Rho and Ras signaling
Rho 和 Ras 信号传导对 p21waf1/cip1 的调节
  • 批准号:
    7277246
  • 财政年份:
    2003
  • 资助金额:
    $ 18.23万
  • 项目类别:
Regulation of p21waf1/cip1 by Rho and Ras signaling
Rho 和 Ras 信号传导对 p21waf1/cip1 的调节
  • 批准号:
    7127690
  • 财政年份:
    2003
  • 资助金额:
    $ 18.23万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 18.23万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了